Neuroprotection Market

Neuroprotection Market (Product: Free Radical Trapping Agents [Antioxidants], Glutamate Antagonists [Anti-excitotoxic Agents], Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors [NTFs], Metal Ion Chelators, Stimulants, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

Neuroprotection Market Outlook 2031

  • The global industry was valued at US$ 31.6 Bn in 2022
  • It is estimated to grow at a CAGR of 7.5% from 2023 to 2031 and reach US$ 60.1 Bn by the end of 2031

Analyst Viewpoint

Increase in prevalence of neurological disorders is boosting the global neuroprotection market size. Rise in geriatric population, prevalence of stressful work environment, and growth in adoption of sedentary lifestyle are contributing to high cases of dementia, stroke, and Parkinson’s. Neuroprotection agents offer mechanisms to mitigate symptoms of neurodegenerative issues in an attempt to enhance patients’ quality of life and health.

Surge in healthcare investment is also augmenting the neuroprotection industry value. Growth in need for advanced critical care solutions has resulted in substantial investments in neuroprotection research. Prominent players operating in the global neuroprotection market are engaged in development of novel therapeutics and advancements in neural protection agents to expand their product portfolio and meet the rising demand worldwide.

Neuroprotection Market

Market Introduction

Neuroprotection refers to a spectrum of strategies and interventions aimed to safeguard the structure and function of the nervous system, especially the brain, and preventing or slowing down the progression of neurodegenerative diseases. These interventions are vital in combating illnesses such as Alzheimer’s, Parkinson's, and stroke.

Neuroprotective agents can encompass pharmaceutical drugs and lifestyle modifications, all with the primary goal of mitigating neuronal damage. Symptoms of neurodegeneration include cognitive impairment such as memory loss, impaired judgment, and motor dysfunction such as muscle stiffness or slowed movement.

Benefits of using neuroprotective agents include improved patient outcomes, enhanced quality of life, and reduced burden to the national healthcare system associated with long-term critical care.

Recent neuroprotection market trends involve advancements in precision medicine, targeted drug delivery, and development of novel therapeutics.

Increase in Prevalence of Neurological Disorders Driving Neuroprotection Market Growth

Significant growth in prevalence of neurodegenerative illnesses such as Alzheimer’s and Parkinson’s can be ascribed to several factors such as rise in geriatric population, increase in pollution, and adoption of sedentary lifestyle.

As per a United Nations study, around 1 billion individuals, approximately one-sixth of the global population, are afflicted with neurological disorders. These conditions range from Alzheimer's and Parkinson's diseases to strokes, multiple sclerosis, epilepsy, and migraines.

The study further mentions that an estimated 6.8 million people succumb to these conditions per year. About 50 million individuals worldwide suffer from epilepsy, while more than 24 million live with symptoms of Alzheimer’s and other dementias. Around 2.5 million individuals globally suffer from multiple sclerosis, while Parkinson’s affects over 10 million people annually.

The neuroprotection industry consists of systems or agents that offer interventions via several mechanisms such as reduction of oxidative stress, inflammation, improvement of neuroplasticity, and rapid healing of damaged tissue.

Overall, these agents assist in mitigating ailments, slowing disease progression, and enhancing the quality of life of the patient, while reducing critical care costs. This is boosting neuroprotection market demand.

Surge in Healthcare Investment Propelling Market Expansion

Increase in awareness about several chronic illnesses and the imperative need for advanced critical care solutions have led to an expansion in healthcare infrastructure and growth in investments in research.

Rise in the elderly population and life expectancy in general is leading to significant growth in patients suffering from Alzheimer’s, Parkinson’s, and strokes. This, in turn, is augmenting the funding required to address these healthcare challenges.

According to the Alzheimer’s Association, the institution invested US$ 100 Mn in dementia research in 2023. As per Alzheimer Disease International, the annual global cost of dementia stands at more than US$ 1.3 Trn and is expected to rise to US$ 2.8 Trn by 2030.

Investments in neuroprotection are pivotal to maintaining the nervous system’s health and mitigating degrading symptoms. Funds are directed toward innovative therapies, precision medicine methods, and drug discovery approaches or clinical trials, thereby fostering neuroprotection market opportunities for companies operating in the landscape.

Regional Outlook

North America accounted for the dominant neuroprotection market share in 2022. Surge in neurodegenerative disorders and increase in healthcare spending are augmenting the market dynamics of the region.

As per a report from the Alzheimer's Disease Association in 2022, nearly 6.2 million people in the U.S. suffer from Alzheimer’s disease. Similarly, according to the Parkinson’s Foundation, an estimated one million adults in the U.S. live with Parkinson’s disease. This number is likely to reach 1.2 million by 2030.

According to the latest neuroprotection market regional insights, the landscape in Asia Pacific appears promising owing to the region’s high-stress work culture and surge in geriatric population, which is prone to neurological issues.

Governments of several countries in Asia Pacific are working on improving their national healthcare infrastructure and accessibility to raise awareness about neurodegenerative illnesses such as dementia and Parkinson’s.

Analysis of Key Players

As per the latest neuroprotection market analysis, prominent manufacturers are investing substantially in the development of neuroprotective therapeutics and neuroprotective drugs to combat the prevalence of neurological issues.

Increase in focus on geographical expansion and improvement in product portfolio via close collaborations are key strategies followed by the leading players in the global landscape.

Daiichi Sankyo Company, Eli Lilly and Company, AbbVie Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc., Astrocyte Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, and Biogen Inc. are key firms operating in neuroprotection sector.

These companies have been profiled in the neuroprotection market research report based on parameters such as company overview, product portfolio, business strategies, financial overview, and business segments.

Key Developments

  • In November 2023, the US Food and Drug Administration (FDA) met with BrainStorm Cell Therapeutics to discuss NurOwn, a device with the potential to alleviate symptoms of ALS. The meeting discussed the overall protocol design of a potential confirmatory Phase III trial.
  • In June 2023, Argenica Therapeutics Pty. Ltd. raised around AU$ 4.0 Mn (US$ 2.7 Mn) to advance a neuroprotective agent clinical trial that assists in reducing brain tissue death after stroke

Neuroprotection Market Snapshot

Attribute Detail
Market Value in 2022 (Base Year) US$ 31.6 Bn
Market Forecast Value in 2031 US$ 60.1 Bn
Growth Rate (CAGR) 7.5%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis.
Competition Landscape
  • Prominent Players – Competition Dashboard and Revenue Share Analysis, 2022
  • Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)
Format Electronic (PDF) + Excel
Market Segmentation
  • Products
    • Free Radical Trapping Agents (Antioxidants)
    • Glutamate Antagonists (Anti-excitotoxic Agents)
    • Apoptosis Inhibitors
    • Anti-inflammatory Agents
    • Neurotrophic Factors (NTFs)
    • Metal Ion Chelators
    • Stimulants
    • Others
  • Application
    • Prevention
    • Treatment
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia
  • Japan
  • China
  • India
  • Brazil
  • Mexico
  • GCC
  • South Africa
Companies Profiled
  • Daiichi Sankyo Company
  • Eli Lilly and Company
  • AbbVie Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • AstraZeneca plc.
  • Astrocyte Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • Biogen Inc.
Customization Scope Available upon Request
Pricing Available upon Request

Frequently Asked Questions

How big was the global neuroprotection market in 2022?

It was valued at US$ 31.6 Bn in 2022

How is the neuroprotection business expected to grow by 2031?

It is projected to grow at a CAGR of 7.5% from 2023 to 2031

What are the key factors driving the demand for neuroprotection?

Increase in prevalence of neurological disorders and surge in healthcare investment

Which neuroprotection application segment held the largest share in 2022?

The treatment segment accounted for the largest share in 2022

Which was the major region in the global neuroprotection landscape in 2022?

North America was the leading region in 2022

Who are the key neuroprotection agent manufacturers?

Daiichi Sankyo Company, Eli Lilly and Company, AbbVie Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc., Astrocyte Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, and Biogen Inc.

    1. Executive Summary

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Neuroprotection Market

    4. Market Overview

        4.1. Market Segmentation

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Neuroprotection Market Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Disease Prevalence & Incidence Rate Globally with Key Countries

        5.3. COVID-19 Pandemic Impact on Industry

    6. Neuroprotection Market Analysis and Forecast, By Product

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, By Product, 2017–2031

            6.3.1. Free Radical Trapping Agents (Antioxidants)

            6.3.2. Glutamate Antagonists (Anti-excitotoxic Agents)

            6.3.3. Apoptosis Inhibitors

            6.3.4. Anti-inflammatory Agents

            6.3.5. Neurotrophic Factors (NTFs)

            6.3.6. Metal Ion Chelators

            6.3.7. Stimulants

            6.3.8. Others

        6.4. Market Attractiveness, By Product

    7. Global Neuroprotection Market Analysis and Forecast, by Application

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Application, 2017–2031

            7.3.1. Prevention

            7.3.2. Treatment

        7.4. Market Attractiveness, by Application

    8. Global Neuroprotection Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region, 2017–2031

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness, by Region

    9. North America Neuroprotection Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, By Product, 2017–2031

            9.2.1. Free Radical Trapping Agents (Antioxidants)

            9.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)

            9.2.3. Apoptosis Inhibitors

            9.2.4. Anti-inflammatory Agents

            9.2.5. Neurotrophic Factors (NTFs)

            9.2.6. Metal Ion Chelators

            9.2.7. Stimulants

            9.2.8. Others

        9.3. Market Value Forecast, by Application, 2017–2031

            9.3.1. Prevention

            9.3.2. Treatment

        9.4. Market Value Forecast, by Country, 2023–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Product

            9.5.2. By Application

            9.5.3. By Country

    10. Europe Neuroprotection Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, By Product, 2017–2031

            10.2.1. Free Radical Trapping Agents (Antioxidants)

            10.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)

            10.2.3. Apoptosis Inhibitors

            10.2.4. Anti-inflammatory Agents

            10.2.5. Neurotrophic Factors (NTFs)

            10.2.6. Metal Ion Chelators

            10.2.7. Stimulants

            10.2.8. Others

        10.3. Market Value Forecast, by Application, 2017–2031

            10.3.1. Prevention

            10.3.2. Treatment

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Product

            10.5.2. By Application

            10.5.3. By Country/Sub-region

    11. Asia Pacific Neuroprotection Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, By Product, 2017–2031

            11.2.1. Free Radical Trapping Agents (Antioxidants)

            11.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)

            11.2.3. Apoptosis Inhibitors

            11.2.4. Anti-inflammatory Agents

            11.2.5. Neurotrophic Factors (NTFs)

            11.2.6. Metal Ion Chelators

            11.2.7. Stimulants

            11.2.8. Others

        11.3. Market Value Forecast, by Application, 2017–2031

            11.3.1. Prevention

            11.3.2. Treatment

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Product

            11.5.2. By Application

            11.5.3. By Country/Sub-region

    12. Latin America Neuroprotection Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, By Product, 2017–2031

            12.2.1. Free Radical Trapping Agents (Antioxidants)

            12.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)

            12.2.3. Apoptosis Inhibitors

            12.2.4. Anti-inflammatory Agents

            12.2.5. Neurotrophic Factors (NTFs)

            12.2.6. Metal Ion Chelators

            12.2.7. Stimulants

            12.2.8. Others

        12.3. Market Value Forecast, by Application, 2017–2031

            12.3.1. Prevention

            12.3.2. Treatment

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Product

            12.5.2. By Application

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Neuroprotection Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, By Product, 2017–2031

            13.2.1. Free Radical Trapping Agents (Antioxidants)

            13.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)

            13.2.3. Apoptosis Inhibitors

            13.2.4. Anti-inflammatory Agents

            13.2.5. Neurotrophic Factors (NTFs)

            13.2.6. Metal Ion Chelators

            13.2.7. Stimulants

            13.2.8. Others

        13.3. Market Value Forecast, by Application, 2017–2031

            13.3.1. Prevention

            13.3.2. Treatment

        13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Product

            13.5.2. By Application

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. Daiichi Sankyo Company

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Treatment Type Portfolio

                14.3.1.3. Financial Overview

                14.3.1.4. SWOT Analysis

                14.3.1.5. Strategic Overview

            14.3.2. Eli Lilly and Company

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Treatment Type Portfolio

                14.3.2.3. Financial Overview

                14.3.2.4. SWOT Analysis

                14.3.2.5. Strategic Overview

            14.3.3. AbbVie Inc.

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Treatment Type Portfolio

                14.3.3.3. Financial Overview

                14.3.3.4. SWOT Analysis

                14.3.3.5. Strategic Overview

            14.3.4. Dr. Reddy's Laboratories Ltd.

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Treatment Type Portfolio

                14.3.4.3. Financial Overview

                14.3.4.4. SWOT Analysis

                14.3.4.5. Strategic Overview

            14.3.5. Teva Pharmaceutical Industries Ltd.

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Treatment Type Portfolio

                14.3.5.3. Financial Overview

                14.3.5.4. SWOT Analysis

                14.3.5.5. Strategic Overview

            14.3.6. Novartis AG

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Treatment Type Portfolio

                14.3.6.3. Financial Overview

                14.3.6.4. SWOT Analysis

                14.3.6.5. Strategic Overview

            14.3.7. AstraZeneca plc.

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Treatment Type Portfolio

                14.3.7.3. Financial Overview

                14.3.7.4. SWOT Analysis

                14.3.7.5. Strategic Overview

            14.3.8. Astrocyte Pharmaceuticals, Inc.

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Treatment Type Portfolio

                14.3.8.3. Financial Overview

                14.3.8.4. SWOT Analysis

                14.3.8.5. Strategic Overview

            14.3.9. F. Hoffmann-La Roche AG

                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.9.2. Treatment Type Portfolio

                14.3.9.3. Financial Overview

                14.3.9.4. SWOT Analysis

                14.3.9.5. Strategic Overview

            14.3.10. Biogen Inc.

                14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.10.2. Treatment Type Portfolio

                14.3.10.3. Financial Overview

                14.3.10.4. SWOT Analysis

                14.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

    Table 02: Global Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 03: Global Neuroprotection Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 04: North America Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

    Table 05: North America Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 06: North America Neuroprotection Market Value (US$ Mn) Forecast, by Country, 2023–2031

    Table 07: Europe Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

    Table 08: Europe Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 09: Europe Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

    Table 11: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 12: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Latin America Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

    Table 14: Latin America Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 15: Latin America Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 16: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

    Table 17: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 18: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Neuroprotection Market Value Share Analysis, By Product 2022 and 2031

    Figure 03: Global Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

    Figure 04: Global Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

    Figure 05: Global Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

    Figure 06: Global Neuroprotection Market Value Share Analysis, by Region, 2022 and 2031

    Figure 07: Global Neuroprotection Market Attractiveness Analysis, by Region, 2023–2031

    Figure 08: North America Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

    Figure 09: North America Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031

    Figure 10: North America Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

    Figure 11: North America Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

    Figure 12: North America Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

    Figure 13: North America Neuroprotection Market Value Share Analysis, by Country, 2022 and 2031

    Figure 14: North America Neuroprotection Market Attractiveness Analysis, by Country, 2023–2031

    Figure 15: Europe Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

    Figure 16: Europe Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031

    Figure 17: Europe Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

    Figure 18: Europe Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

    Figure 19: Europe Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

    Figure 20: Europe Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 21: Europe Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 22: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

    Figure 23: Asia Pacific Neuroprotection Market Value Share Analysis, By Product 2022 and 2031

    Figure 24: Asia Pacific Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

    Figure 25: Asia Pacific Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

    Figure 26: Asia Pacific Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

    Figure 27: Asia Pacific Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 28: Asia Pacific Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 29: Latin America Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

    Figure 30: Latin America Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031

    Figure 31: Latin America Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

    Figure 32: Latin America Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

    Figure 33: Latin America Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

    Figure 34: Latin America Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 35: Latin America Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 36: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

    Figure 37: Middle East & Africa Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031

    Figure 38: Middle East & Africa Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

    Figure 39: Middle East & Africa Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

    Figure 40: Middle East & Africa Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

    Figure 41: Middle East & Africa Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 42: Middle East & Africa Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 43: Global Neuroprotection Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved